You are here

P&T May 2019


Congress Doesn’t Know, Doesn’t Care
What lies behind the growth of rising hospital prices? Many factors–including the impact of hospital mergers and the industry’s complicated relationship with Congress.
VR in pharmacy has huge potential: drug design and discovery, pharmacist education, patient counseling/behavior modification, and more. Today’s technology is more affordable, flexible, and portable, and eminently suitable for therapeutic purposes. But despite VR’s compelling features, challenges remain, such as validating clinical efficacy, cost/accessibility issues, technical capabilities, and consumer acceptance.
Meeting Highlights

We report on two sessions on atrial fibrillation, two on heart failure, two on hypertension, and one each on endocarditis and ST-elevation myocardial infarction.

Guided by a New Research Framework, the Field is Poised For Greater Precision and Promising Horizons
This in-depth article on the sixth leading cause of death in the U.S. reports on the optimism of cutting-edge leaders in Alzheimer’s disease research. The author examines key considerations such as the status of biomarker tests, and the search for new biomarkers; securing an accurate definition of the disease; risk factors; clinical trials and non-pharmacological studies.
Health Care & Law
Increased cannabis use has brought about a sea change in policy and attitudes toward regulation, and a multitude of rules that vary widely between states. The disparity has stymied any effective response to the problems surrounding access to cannabis products for those in need. Health care providers and practitioners, as well as P&T committees, must carefully undertake decisions on rational drug use, whether or not their patients are using cannabis while under their care.


Medication Errors
Indication-based prescribing has many potential benefits, including preventing errors by reducing medication choices and assisting with medication reconciliation.
Prescription: Washington
How easy is it for generics to enter the market? It could be easier with legislation that opens up the field for generic competitors, but it is unlikely that such a bill will ever be introduced.
Approvals, new indications and formulations, and safety issues
Cablivi (caplacizumab-yhdp) for acquired thrombotic thrombocytopenic purpura; Egaten (triclabendazole) for fascioliasis; and Spravato (esketamine) for treatment-resistant depression
Drug Forecast
Cannabidiol oral solution for seizures associated with Lennox-Gastaut and Dravet syndromes